ORGO Organogenesis
Organogenesis earnings company data as of 4:46 AM ET 10/25
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by ORGO's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $40K bought by 2 insiders
- $2.6M sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Arthur S Leibowitz DirectorBuy$13K 5,000 shares at $2.68 +1.7% to stakeTraded Mar 9 Filed Mar 11
-
Michael Joseph Driscoll DirectorBuy$27K 10,000 shares at $2.67 +4.6% to stakeTraded Mar 9 Filed Mar 11
-
Glenn H Nussdorf DirectorSale$1M 200,000 shares at $5.14 7.2% of stakeTraded Dec 16, 2025 Filed Dec 18, 2025
-
Glenn H Nussdorf DirectorSale$1.6M 300,000 shares at $5.31 9.8% of stakeTraded Nov 24–26 Filed Nov 26, 2025
-
Glenn H Nussdorf DirectorBuy$1.1M 358,495 shares at $3.06 New stakeTraded May 14–15 Filed Nov 3, 2025
-
Glenn H Nussdorf DirectorSale$81K 22,776 shares at $3.55 6.4% of stakeTraded Jun 9–10 Filed Nov 3, 2025
Also filed in the last 12 months, not counted as buying or selling: 35 share withholdings for taxes and 14 stock grants.
SEC filings
Recent issuer filings from EDGAR, 11 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.